ALLO
Allogene Therapeutics Inc

3,225
Mkt Cap
$323.61M
Volume
819,821.00
52W High
$3.78
52W Low
$0.8621
PE Ratio
-1.47
ALLO Fundamentals
Price
$1.43
Prev Close
$1.44
Open
$1.47
50D MA
$1.27
Beta
1.60
Avg. Volume
2.4M
EPS (Annual)
-$1.32
P/B
1.02
Rev/Employee
$96.07
Loading...
Loading...
News
all
press releases
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen
Wall Street Zen raised Allogene Therapeutics from a "sell" rating to a "hold" rating in a report on Friday...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Foresite Capital Management VI LLC Sells 572,918 Shares of Allogene Therapeutics, Inc. $ALLO
Foresite Capital Management VI LLC decreased its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 16.6% in the 2nd quarter, according to its most recent 13F filing...
MarketBeat·9d ago
News Placeholder
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twelve research firms that are presently covering the firm, MarketBeat...
MarketBeat·16d ago
News Placeholder
HC Wainwright Has Strong Estimate for ALLO FY2025 Earnings
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a report released on Monday...
MarketBeat·22d ago
News Placeholder
Allogene Therapeutics (NASDAQ:ALLO) Issues Earnings Results, Beats Expectations By $0.04 EPS
Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus...
MarketBeat·27d ago
News Placeholder
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
Zacks·28d ago
News Placeholder
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
Zacks·2mo ago
News Placeholder
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
Zacks·2mo ago
News Placeholder
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
Zacks·2mo ago
News Placeholder
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
Zacks·2mo ago

Latest ALLO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.